Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Theravance Biopharma (TBPH) Non-Current Receivables (2017 - 2020)

Theravance Biopharma (TBPH) has disclosed Non-Current Receivables for 4 consecutive years, with $4.0 million as the latest value for Q2 2020.

  • Quarterly Non-Current Receivables rose 7.88% to $4.0 million in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Jun 2020, up 7.88% year-over-year, with the annual reading at $3.7 million for FY2019, N/A changed from the prior year.
  • Non-Current Receivables for Q2 2020 was $4.0 million at Theravance Biopharma, roughly flat from $4.0 million in the prior quarter.
  • The five-year high for Non-Current Receivables was $8.2 million in Q4 2017, with the low at $3.1 million in Q3 2018.
  • Average Non-Current Receivables over 4 years is $4.5 million, with a median of $3.7 million recorded in 2019.
  • The sharpest move saw Non-Current Receivables tumbled 61.2% in 2018, then grew 17.56% in 2019.
  • Over 4 years, Non-Current Receivables stood at $8.2 million in 2017, then plummeted by 61.78% to $3.1 million in 2018, then rose by 17.6% to $3.7 million in 2019, then grew by 8.26% to $4.0 million in 2020.
  • According to Business Quant data, Non-Current Receivables over the past three periods came in at $4.0 million, $4.0 million, and $3.7 million for Q2 2020, Q1 2020, and Q4 2019 respectively.